The Vanguard Group 13D and 13G filings for Relmada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 5:13 pm Sale | 2023-12-29 | 13G | Relmada Therapeutics, Inc. RLMD | The Vanguard Group | 1,310,805 4.350% | -206,175 (-13.59%) | Filing |
| 2023-02-09 11:30 am Purchase | 2022-12-30 | 13G | Relmada Therapeutics, Inc. RLMD | The Vanguard Group | 1,516,980 5.040% | 1,516,980 (New Position) | Filing |